LOXO-305 Trial Begins for Lymphoma, Leukemia Patients Resistant to BTK Inhibitors
News
A Phase 1/2 trial is evaluating Loxo Oncology‘s BTK inhibitor LOXO-305 in leukemia and lymphoma patients who failed, or were intolerant to, approved BTK inhibitors. The trial, so far being conducted ... Read more